EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	**PATRICK REDMOND**

Activities (2021 - 2025)	**Yes/No**	**Period (From - To)**	**Information**	**Details**
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: • **has a value of more than 10.000 EUR, or** • **entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of entity; • Place; • Type of entity: public, private.	[Please describe your role.]

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☒ No ☐	01/2021 – present	RCSI University of Medicine and Health Sciences, Dublin, Ireland. Independent not-for-profit university and research institution. Associate Professor in General Practice. Salaried academic appointment.	My lung cancer research and participation in EU-funded programmes are undertaken through RCSI institutional research agreements. I receive no separate personal remuneration from SOLACE, EUCanScreen or the Lung Health Check programme
B. Consultancy, including advisory activities	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]
C. Non-remunerated post	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'ye's, please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
D. Legal representation[5]	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	05/2025 – ongoing	PI or Co-PI.	1. Beaumont RCSI Irish Cancer Society Lung Health Check pilot — 05/2025–Present. Primary Care Lead and co-investigator/co-lead. Community-based feasibility trial of risk-based low-dose CT lung cancer screening integrated with general practice. The study protocol was published in BMJ Open Respiratory Research in 2025. 2. Tailoring Lung Cancer Screening for Ireland: Using Existing Datasets to Generate Evidence-Based Recommendations for Health Policy (LuCUMO; HRB SDAP-2023-033) — 10/2024–Present. Principal Investigator. Programme of epidemiological and health-economic modelling to inform lung cancer screening policy in Ireland. Protocols and research outputs have been published. 3. Design and Development of a Lung Cancer Screening Recruitment Tool (CLIMBER) — 2023–Present. Principal Investigator. Mixed-methods programme to co-design an

				evidence-based recruitment strategy for lung cancer screening, particularly for high-risk and underserved populations. Study protocol published. 4. Recruitment Strategies for Lung Cancer Screening: An Umbrella Review — EUCanScreen — 06/2024–Present. Investigator and senior supervisor within the RCSI contribution to EUCanScreen. Evidence synthesis examining strategies to improve participation in lung cancer screening, particularly among underserved populations. Protocol published in HRB Open Research in 2025. 5. BIOLUX-Umbrella Study: Umbrella Review of Non-Invasive Biomarkers used to Guide Pre-diagnostic Decision Making in Lung Cancer Screening — 2025–Present. Investigator/senior supervisor. Protocol published in HRB Open Research in 2025. 6. Cohort Study on Lung Cancer Diagnostic Pathways and Outcomes in Ireland — 2025–Present.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
				Investigator/senior supervisor. Retrospective study examining routes to diagnosis, diagnostic timeliness and clinical outcomes. Protocol published in HRB Open Research in 2025. 7. Realist Review of mHealth in Lung Cancer Screening — 2025–Present. Investigator. Evidence synthesis examining mechanisms, contexts and intervention characteristics influencing participation in lung cancer screening. Protocol published in HRB Open Research in 2025.

B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	01/2023 – ongoing	If 'yes', please specify: • Type of received support: grants, funds; • Entity which offered the support: name, place, type (public, private); • Received amounts (for public grants please also specify the annual budget of your home institution).	All research support listed below is provided to and administered through RCSI University of Medicine and Health Sciences and/or partner institutions under institutional agreements. I have not received personal consultancy payments, honoraria or other personal remuneration from these grants. SOLACE – Strengthening the Screening of Lung Cancer in Europe (EU4Health Grant Agreement 101101187). RCSI institutional award: €513,000. Project period: 04/2023–03/2026. EUCanScreen – Implementation of Cancer Screening Programmes (EU4Health Grant Agreement 101162959). RCSI institutional funding: €50,172. Project period: 06/2024–05/2028. Tailoring Lung Cancer Screening for Ireland (LuCUMO), Health Research Board Secondary Data Analysis Project SDAP-2023-033. RCSI institutional award: €246,981.

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
				Principal Investigator: Patrick Redmond. Beaumont RCSI Irish Cancer Society Lung Cancer Outreach Programme/Lung Health Check. The Lung Health Check is Flagship Project 1 within the six-year Beaumont RCSI Irish Cancer Society Lung Cancer Outreach Programme. The Irish Cancer Society has committed €4.9 million to the overall programme; this figure is for the programme as a whole and not solely the Lung Health Check. Funding is administered institutionally through the programme; no personal payment is received by me. Design and Development of a Lung Cancer Screening Recruitment Tool (CLIMBER). HRB Primary Care Clinical Trials Network Ireland Seed Funding Award, administered through RCSI. No personal payment received.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	04/2023 – ongoing	If 'yes', please specify: • Name, • Place; • Type: public, private, etc. (list all if more than one).	SOLACE – Strengthening the Screening of Lung Cancer in Europe. European EU4Health-funded multidisciplinary collaborative programme. 04/2023–03/2026. Academic contributor through RCSI, with particular involvement in primary care integration, implementation and participation in lung cancer screening. Participation is through an RCSI institutional agreement; no personal remuneration. EUCanScreen – Implementation of Cancer Screening Programmes. EU4Health Joint Action, Grant Agreement 101162959. 06/2024–Present. Academic contributor through RCSI, including work on evidence synthesis and strategies to support equitable participation in lung cancer screening. Participation is through an RCSI institutional agreement; no personal remuneration.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the activity.	[Please describe the activity.]

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname: **PATRICK REDMOND** **Date:** **28/8/26**

Signature:  **Place: Dublin, Ireland**

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656

[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725